Streptozotocin-Based Chemotherapy is Still Alive in Patients with Neuroendocrine Neoplasms: Predictive and Prognostic Markers for Treatment und Survival Abstract #1009

Introduction: Chemotherapy with Streptozotocin (STZ) and 5-FU or Doxorubicin (Doc) represents a standard of care for patients with well-differentiated metastatic neuroendocrine neoplasms, especially for the pancreas (PNENs). However, data to identify predictive and prognostic markers are limited.
Aim(s): Evaluation of clinicopathological characteristics and possible predictive and prognostic markers of patients receiving this combination.
Materials and methods: We retrospectively analyzed 77 patients who were treated at the University Hospital Marburg between 1995 and 2013. The median overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier and Cox regression methods, respectively.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: M.D. Sebastian Krug

To read results and conclusion, please login ...

Further abstracts you may be interested in

#852 5-FU-based Chemotherapy in Pancreatic Neuroendocrine Neoplasms: Predictive and Prognostic Markers for Treatment und Survival
Introduction: Chemotherapy with 5-FU and Streptozotocin (STZ) represents a standard of care for patients with metastatic pancreatic neuroendocrine neoplasms (PNENs). However, data to identify predictive and prognostic markers are limited.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: M.D. Sebastian Krug
Authors: Krug S, Boch M, Rinke A, Nimphius W, ...
Keywords: 5-fluorouracil, DPD, PNEN
#853 Paraneoplastic Encephalitis in a Patient with Exceptionally Long Survival Despite a Hepatic Metastatic Neuroendocrine Rectum Neoplasm
Introduction: We report the instructive case of a woman that was diagnosed with a neuroendocrine neoplasm (NEN) of the rectum with multiple liver metastases, who subsequently developed an anti-Ri positive paraneoplastic neurological syndrom (PNS).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Clinical cases/reports
Presenting Author: M.D. Sebastian Krug
Authors: Krug S, Boch M, Seipelt M, Rexin P, ...
Keywords: rectum, anti-Ri, TACE, PNS
#2793 A Phase II, Open-Label, Multicenter Trial of Avelumab in Patients with Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive after First-line Chemotherapy (AVENEC)
Introduction: High grade Neuroendocrine Neoplasias (NEN) are rare tumors with a poor prognosis and no established second line therapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: PD. Dr. Christian Fottner
#754 Effect of Dacarbazine Chemotherapy in Well-Differentiated Neuroendocrine Tumors
Introduction: Streptozocin-based chemotherapies are widely used in pancreatic NEN. Dacarbazine (DTIC) (650mg/m2 every four weeks) can easily be applied in an outpatient setting, but data on efficacy are limited.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Daniela Mueller
Authors: Mueller D, Krug S, Majumder M, Gress T, ...
Keywords: NEN, DTIC, MGMT
#2891 Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid
Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Eleni Armeni